2-MMC (2-Methylmethcathinone): Complete Human Toxicology, Metabolism & Safety Monograph
What the evidence actually shows
Evidence Emerging moderate human forensic evidence; direct in-vitro metabolism/pharmacology; limited controlled human clinical pharmacologyDirect answer
Reference-grade 2-MMC monograph covering identity, 3-MMC/4-MMC relationship, monoamine pharmacology, a 2026 13-case human/forensic series, fatal multidrug evidence, metabolism, positional-isomer testing, tolerance, stimulant dependence/withdrawal, treatment, forensic interpretation, EU control, and U.S. Schedule I positional-isomer status. 2-MMC (CAS 1246815-51-9) is the ortho positional isomer of 3-MMC and 4-MMC/mephedrone, sharing the same molecular formula but requiring analytical separation to identify correctly. Routine amphetamine/MDMA immunoassays can behave unpredictably: 2-MMC can cross-react at high concentrations, while a negative or generic positive result cannot establish molecular identity.
Research brief
Questions this page answers
- What is 2-MMC or ortho-mephedrone?
- How is 2-MMC different from 3-MMC and 4-MMC?
- Has 2-MMC been found in human intoxications or deaths?
- Can 2-MMC cause stimulant psychosis, cardiovascular toxicity, or hyperthermia?
- How is 2-MMC metabolized?
- Can laboratories distinguish 2-MMC from 3-MMC and 4-MMC?
- Can routine drug screens detect 2-MMC?
- Can 2-MMC cause tolerance, dependence, or withdrawal?
- Does a 2-MMC blood concentration predict impairment or death?
- Is 2-MMC controlled in the United States and European Union?
Signal
Scientific takeaways
- 2-MMC (CAS 1246815-51-9) is the ortho positional isomer of 3-MMC and 4-MMC/mephedrone, sharing the same molecular formula but requiring analytical separation to identify correctly.
- A 2026 French series described 13 analytically investigated 2-MMC cases: eight living patients and five deceased people across DUID, chemsex, drug-facilitated crime, suicide, and other forensic contexts.
- Postmortem blood concentrations in that series ranged from 4.7 to 3,030 ng/mL and clinical/other plasma concentrations from 106 to 218 ng/mL; those ranges are context data, not impairment or lethal thresholds.
- A separate 2026 fatal NPS poly-consumption case measured 2-MMC at 12,616 ng/mL alongside bromazolam, O-desmethyltramadol, 4-FMA and 4F-MPH; the death was attributed to the toxicological mixture, not 2-MMC alone.
- Human-liver and casework research identifies hydroxylated, N-desmethyl and keto-reduced metabolites; CYP2D6 is an important enzyme in methylmethcathinone metabolism in vitro.
- 2-, 3-, and 4-MMC can be misidentified if an analytical method does not resolve positional isomers; a 2025 oral-fluid reanalysis changed many earlier '4-MMC' identifications to 2-MMC or 3-MMC.
- Routine amphetamine/MDMA immunoassays can behave unpredictably: 2-MMC can cross-react at high concentrations, while a negative or generic positive result cannot establish molecular identity.
- EU-wide control measures for 2-MMC entered into force in January 2026; in the United States, positional isomers of Schedule I mephedrone have been federally controlled since 2012 even though 2-MMC does not have its own standalone DEA drug code.
2-MMC (2-Methylmethcathinone): Complete Human Toxicology, Metabolism & Safety Monograph
Emergency stimulant toxicity: Severe agitation/confusion, dangerous overheating, seizure, chest pain, collapse, very fast/irregular heartbeat, loss of consciousness, or behavior that cannot be kept safe after an unknown stimulant requires urgent medical care.
Quick answer
2-MMC is 2-methylmethcathinone, the ortho positional isomer of 3-MMC and 4-MMC/mephedrone.
For years it had little direct human evidence.
That changed sharply in 2025–2026.
The evidence now includes:
- a 13-case French clinical/forensic series;
- five postmortem cases within that series;
- a separate fatal multidrug case with very high 2-MMC exposure;
- modern human-liver metabolism studies;
- human oral-fluid studies demonstrating major positional-isomer misclassification in older/nonselective methods;
- European population-risk assessment and control.
Identity
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Field | Evidence-based answer |
|---|---|
| Canonical name | 2-Methylmethcathinone (2-MMC) |
| Informal name | Ortho-mephedrone |
| CAS | 1246815-51-9 |
| Formula / molecular mass | C11H15NO / 177.24 g/mol |
| Family | Methylmethcathinone synthetic cathinone |
| Positional isomers | 3-MMC and 4-MMC/mephedrone |
| Main pharmacology | Monoaminergic stimulant / transporter substrate-release profile |
| Approved medical use | None |
History and market emergence
2-MMC has been reported in Europe since at least 2013, but its prevalence rose sharply after controls reduced availability of 3-MMC and other cathinones.
EUDA's 2025 risk assessment described a major growth in availability after 2022.
Across EU data from 2013–2024, thousands of detections and large-scale seizures were reported.
The 2025 Dutch review similarly described 2-MMC as an increasingly important substitute in the stimulant market.
Relationship to 3-MMC and 4-MMC
2-MMC, 3-MMC and 4-MMC:
- have the same molecular formula;
- share the methcathinone scaffold;
- differ only in where the ring methyl group sits.
That small structural difference matters for:
- transporter pharmacology;
- metabolism;
- analytical retention time;
- legal identity.
A mass spectrum that does not resolve positional isomers can assign the wrong drug.
Pharmacology
Experimental work on substituted methcathinones supports a monoamine-releasing/transporter-substrate profile.
2-MMC affects:
- dopamine;
- norepinephrine;
- serotonin.
Available structure-activity evidence suggests a relatively more catecholaminergic and less serotonergic profile than 4-MMC.
This can help explain stimulant-like effects but does not create a dose conversion to 3-MMC or mephedrone.
Human evidence: 13 French cases
A 2026 International Journal of Legal Medicine series reported 13 men aged 19–63 years with 2-MMC exposure.
Contexts included:
- driving under the influence;
- chemsex;
- drug-facilitated crime;
- suicide;
- postmortem investigation.
The series included:
- eight living individuals;
- five deceased individuals.
Concentrations
Postmortem blood ranged from:
- 4.7 to 3,030 ng/mL.
Clinical/other plasma samples ranged from:
- 106 to 218 ng/mL.
These are descriptive forensic ranges.
They are not validated:
- impairment thresholds;
- lethal thresholds;
- dose calculators.
Fatality evidence
Five deceased cases in the 2026 series
The French Alps series includes five deceased people with 2-MMC detected.
That proves postmortem relevance.
It does not mean 2-MMC alone caused each death.
Case-specific co-drugs, circumstances and pathology remain essential.
Fatal NPS poly-consumption
A separate 2026 French case involved a 42-year-old woman who died with multiple NPS present.
Peripheral blood contained:
- 2-MMC: 12,616 ng/mL;
- bromazolam;
- O-desmethyltramadol;
- 4-FMA;
- 4F-MPH.
Investigators concluded the death was toxicological and due to the drug mixture.
The very high 2-MMC concentration is important but cannot be converted into a universal lethal concentration.
Acute toxicity
Direct human data remain smaller than for 3-MMC/4-MMC, but stimulant-class and case evidence support concern for:
- tachycardia;
- hypertension;
- agitation;
- anxiety/panic;
- insomnia;
- paranoia;
- stimulant-induced psychosis;
- hyperthermia;
- seizures;
- cardiovascular collapse in severe poisoning.
Psychiatric toxicity
Cathinone stimulant exposure can produce:
- paranoia;
- persecutory thinking;
- agitation;
- hallucinations;
- psychosis.
Risk is amplified by:
- repeated dosing;
- prolonged wakefulness;
- other stimulants;
- psychiatric vulnerability.
The exact incidence for 2-MMC is unknown.
Cardiovascular and temperature risk
Catecholaminergic stimulation can increase:
- heart rate;
- blood pressure;
- myocardial demand;
- body temperature.
No controlled 2-MMC human study establishes a safe cardiovascular exposure.
Interactions
No controlled 2-MMC interaction trials establish safe combinations.
Potentially dangerous contexts include:
- other stimulants;
- MAO inhibitors;
- serotonergic entactogens;
- alcohol/benzodiazepines masking warning signs;
- opioids causing independent respiratory depression.
The fatal poly-consumption case is direct evidence that 2-MMC occurs in complex NPS combinations.
Metabolism
Human liver microsome studies of methylmethcathinone isomers identify pathways including:
- ring/side-chain hydroxylation;
- N-demethylation;
- keto reduction.
The 2026 clinical/forensic series confirmed several of these metabolites in human casework.
CYP involvement
A 2025 comparative human-liver study identified CYP2D6 as an important enzyme in hydroxylation/demethylation of methylmethcathinones.
That creates plausible pharmacokinetic interaction potential.
The magnitude of real-world interactions has not been quantified in controlled 2-MMC trials.
Pharmacokinetics
No controlled human PK program establishes a universal:
- bioavailability;
- time to peak;
- half-life;
- clearance;
- accumulation profile.
Forensic concentrations at one time point cannot substitute for a PK study.
Testing and toxicology
Routine immunoassays
2-MMC can interfere with some amphetamine-type immunoassays at sufficiently high concentrations.
But this does not make routine immunoassays a reliable 2-MMC test.
A generic positive may be nonspecific, and a negative does not exclude a cathinone.
Definitive testing
Useful methods include:
- LC-MS/MS;
- LC-HRMS/QTOF;
- GC-MS with retention-time separation;
- NMR for drug materials;
- parent plus metabolite targets.
The positional-isomer problem
A 2025 enantioselective oral-fluid study reanalyzed samples originally called mephedrone/4-MMC with a nonselective method.
After better separation:
- only one contained 4-MMC;
- 12 contained 2-MMC;
- six contained 3-MMC;
- four contained both 2-MMC and 3-MMC.
This is powerful evidence that molecular identification can be wrong when the method does not separate isomers.
Product identity and mislabeling
The fatal French NPS case also found a packet labeled 4F-MPH that analytically contained 4-FMA.
The larger lesson applies to 2-MMC too:
A research-chemical bag label is not proof of contents.
Analytical confirmation outranks seller labeling.
Tolerance
Repeated stimulant exposure can produce tolerance.
No 2-MMC-specific human tolerance timeline exists.
Diminished subjective effects do not prove equal tolerance to:
- hypertension;
- hyperthermia;
- psychosis;
- arrhythmia;
- sleep deprivation.
Dependence and stimulant use disorder
2-MMC-specific dependence incidence is unknown.
Its monoaminergic stimulant pharmacology supports credible risk of:
- craving;
- repeated redosing;
- binge use;
- inability to cut down;
- continued use despite medical or psychiatric harm.
Stimulant withdrawal
After heavy/repeated stimulant use, withdrawal can include:
- fatigue;
- hypersomnia or insomnia;
- depressed mood;
- anhedonia;
- irritability;
- slowed thinking;
- increased appetite;
- craving.
There is no validated 2-MMC-specific withdrawal clock.
Severe depression, suicidality or persistent psychosis requires urgent evaluation.
Treatment and support
There is no medication approved specifically for 2-MMC use disorder.
The ASAM/AAAP stimulant-use-disorder guideline identifies contingency management as a core evidence-based behavioral intervention, often alongside CBT/community-reinforcement approaches.
Acute treatment is complication-directed.
U.S. resources include FindTreatment.gov and SAMHSA 1-800-662-HELP (4357).
Forensic interpretation
Detection does not establish cause
Five postmortem detections in one series do not mean five 2-MMC-only deaths.
Concentration does not equal dose
Blood concentration depends on:
- timing;
- route;
- tolerance;
- co-drugs;
- specimen;
- postmortem change.
Positional-isomer certainty matters
A concentration reported as 2-MMC is useful only if the method adequately distinguishes it from 3-MMC and 4-MMC.
Special populations
Controlled 2-MMC studies are inadequate for:
- pregnancy/breastfeeding;
- adolescents;
- cardiovascular disease;
- seizure disorders;
- serious psychiatric illness;
- liver/kidney disease.
Missing evidence should not be interpreted as safety.
Legal status — dated October 3, 2026
European Union
EU control legislation covering 2-MMC, NEP and 4-BMC entered into force in January 2026, requiring Member States to implement national controls by July 2026.
United States
Mephedrone/4-MMC is Schedule I.
DEA's 2023 federal rule states that positional isomers of mephedrone have been subject to permanent Schedule I control since July 9, 2012.
2-MMC is a positional isomer of mephedrone.
Unlike 3-MMC, it does not currently have its own separately enumerated DEA drug code in the cited rule.
International
UNODC tracks 2-MMC as a stimulant NPS.
This review does not identify a UN convention scheduling decision specifically placing 2-MMC under international control as of October 3, 2026.
Myths and misconceptions
"2-MMC is just weaker 3-MMC."
Not established. Positional isomers can differ substantially in pharmacology and metabolism.
"A mephedrone result automatically tells you which MMC isomer was present."
False.
"The 12,616 ng/mL fatal-case concentration is the lethal threshold."
False. It was a complex multidrug death.
"A routine amphetamine test identifies 2-MMC."
Not specifically.
"No dedicated human trial means there is no human evidence."
Outdated. A 13-case human/forensic series is now published.
Evidence ledger
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Status | Current conclusion |
|---|---|
| Established | 2-MMC is a real methylmethcathinone stimulant; human clinical/forensic exposures and postmortem cases are documented; metabolism is increasingly characterized; positional-isomer separation is crucial. |
| Strongly supported | Sympathomimetic toxicity, tolerance, compulsive use, stimulant withdrawal and psychiatric/cardiovascular harm are credible risks. |
| Uncertain | Human PK, dependence incidence, isolated-drug lethality, long-term effects and concentration–impairment relationships. |
| Not established | Safe recreational dose, 3-MMC/4-MMC equivalence, universal fatal concentration, or 2-MMC-specific medication treatment. |
Related evidence
- 3-MMC
- 4-MMC / Mephedrone
- 3-CMC
- N-Ethylhexedrone
- NEP / N-Ethylpentedrone
- Synthetic cathinones & RC stimulants
- Substance Use, Dependence & Harm Reduction hub
Bottom line
2-MMC can no longer be dismissed as an evidence-empty substitute cathinone.
By 2026, the literature contains a 13-case human/forensic series, multiple postmortem cases, a fatal multidrug investigation with very high exposure, metabolism data, and strong evidence that older analytical methods can confuse 2-MMC with 3-MMC or 4-MMC.
The major remaining uncertainty is not whether 2-MMC is a real risk.
It is how to translate a still-small human dataset into population-level toxicity and dependence estimates without pretending to know more than the evidence supports.
Source ledger
References
11 sources
- 01Emergence of 2-MMC in the French Alps: description of 13 clinical and forensic toxicology cases Boudin C, Revol B, Eysseric-Guérin H, et al. · 2026Human analytically confirmedClinical and forensic case seriesPMID 41973121DOI 10.1007/s00414-026-03791-4 PubMed →
- 02First French case of fatal NPS poly-consumption involving bromazolam and 2-MMC: insights from NMR and LC-HRMS Alexandre M, Pelletier R, Le Daré B, et al. · 2026Human fatalityFatal polysubstance case / product analysisPMID 41428037DOI 10.1007/s00414-025-03689-7 PubMed →
- 03Appearance of 2-MMC and 3-MMC on the illicit drug market in the Netherlands: A systematic narrative review of the prevalence and risks van Amsterdam J, et al. · 2025Human/public-health evidence synthesisSystematic narrative reviewPMID 40876068DOI 10.1016/j.drugpo.2025.104971 PubMed →
- 04In vitro metabolism of cathinone positional isomers: does sex matter? Metabolism study authors · 2023In-vitro humanHuman liver microsome metabolismPMID 37452840 PubMed →
- 05Comparative in Vitro Metabolic Profile Study of Five Cathinone Derivatives Metabolism study authors · 2025In-vitro humanHuman liver microsome / CYP metabolismPMID 40103476 PubMed →
- 06Simultaneous enantioselective determination of 2-, 3-, and 4-methylmethcathinones; their isomers; and major phase-1 metabolites in oral fluid of drug abusers Analytical toxicology authors · 2025Human specimens / isomer separationHuman oral-fluid forensic analytical studyPMID 40133647 PubMed →
- 07Underreporting of synthetic cathinone poisoning with clinical immunoassays: An experimental and observational study Clinical analytical toxicology investigators · 2025Human observational + analyticalClinical immunoassay / mass-spectrometry comparisonPMID 40118811DOI 10.1177/00045632251331404 PubMed →
- 082-methylmethcathinone — Substance Details United Nations Office on Drugs and Crime Early Warning Advisory · 2026Authoritative referenceChemical identity / international surveillance Source →
- 09EU takes action to control three harmful new drugs European Union Drugs Agency · 2026Authoritative regulatory sourceEuropean legal/public-health action Source →
- 10Specific Listing for Three Currently Controlled Schedule I Substances U.S. Drug Enforcement Administration · 2023Authoritative legal sourcePrimary U.S. federal scheduling interpretation Source →
- 11The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder Clinical Guideline Committee · 2024Guideline / systematic evidence reviewClinical practice guidelinePMID 38669101DOI 10.1097/ADM.0000000000001299 PubMed →